Cholesterol drug setback casts doubt over multibillion-dollar race

{
  "signal_id": "0335b146-2672-2c98-6683-7dfa6d0517fa",
  "signal_type": "news",
  "signal_subtype": "is_developing",
  "detected_at": "2026-09-08T05:00:01+00:00",
  "company": {
    "name": "Amgen",
    "domain": "amgen.com"
  },
  "data": {
    "url": "https://www.cnbc.com/2026/09/08/novartis-cholesterol-setback-drug-race-eli-lilly-amgen.html",
    "title": "Cholesterol drug setback casts doubt over multibillion-dollar race",
    "excerpt": "In this article Novartis ' failure in a closely watched cardiovascular trial has raised questions about one of the pharmaceutical industry's biggest drug races and rival treatments from U.S. heavyweights Amgen and Eli Lilly . The pelacarsen drug, developed jointly with Ionis Pharmaceuticals , reduced a particularly harmful form of cholesterol in a late-stage clinical trial, but failed to significantly improve cardiovascular outcomes, Novartis said after the bell on Friday. The stock fell 3% on Monday. It is the first major clinical setback in the race to develop treatments that lower Lp(a), which elevates cardiovascular risks that are estimated to affect roughly one in five people worldwide and for which there is currently no approved targeted treatment. Although Amgen and Lilly are testing different technologies that have been shown to produce deeper reductions in the cholesterol called Lp(a), analysts say pelacarsen's failure raises the risk around a market that market watchers expect to be worth billions of dollars. \"The Lp(a) hypothesis is weakened, but not disproven,\" Citi analysts said in a research note, noting that details remain scarce beyond the topline miss, including the magnitude by which pelacarsen lowered Lp(a) levels. More data is needed to determine whether the miss reflects pelacarsen's mechanism, trial design, or a challenge to the whole hypothesis that...",
    "product": "olpasiran",
    "summary": "Amgen is developing a drug, olpasiran, to lower Lp(a) cholesterol as a rival treatment to Novartis's pelacarsen.",
    "planning": true,
    "image_url": "https://image.cnbcfm.com/api/v1/image/108297645-1777300177064-108297645-1777300126332-gettyimages-1902456631-20231205_225708-4595.jpg?v=1777314002&w=1920&h=1080",
    "confidence": 0.9,
    "product_data": {
      "name": "olpasiran",
      "full_text": "Amgen's competing drug, olpasiran",
      "fuzzy_match": false
    },
    "product_tags": [
      "medical"
    ],
    "published_at": "2026-09-08T05:00:01Z",
    "article_sentence": "Amgen's competing drug, olpasiran, faces the clearest readthrough, while Lilly's medicine, lepodisiran, is being trialled on a broader group of patients, including some who have not yet developed established cardiovascular disease, potentially limiting the direct read-through from Novartis' failure, they said."
  }
}

curl https://signals.autobound.ai/v1/signals/0335b146-2672-2c98-6683-7dfa6d0517fa \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"amgen.com","limit":20}'